Calithera Biosciences, Inc. (NASDAQ:CALA) was downgraded by research analysts at BidaskClub from a “sell” rating to a “strong sell” rating in a report issued on Saturday.

CALA has been the topic of a number of other reports. Zacks Investment Research upgraded Calithera Biosciences from a “hold” rating to a “strong-buy” rating and set a $21.00 target price on the stock in a research report on Tuesday, July 11th. HC Wainwright reiterated a “buy” rating and set a $19.00 target price (up from $14.00) on shares of Calithera Biosciences in a research report on Monday, June 12th. Finally, Wells Fargo & Company reiterated an “outperform” rating and set a $20.00 target price (up from $15.00) on shares of Calithera Biosciences in a research report on Tuesday, June 6th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and four have issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus target price of $15.50.

Shares of Calithera Biosciences (CALA) opened at 13.90 on Friday. Calithera Biosciences has a 52-week low of $2.20 and a 52-week high of $20.05. The stock’s market cap is $493.12 million. The firm has a 50-day moving average price of $15.88 and a 200 day moving average price of $12.74.

Calithera Biosciences (NASDAQ:CALA) last posted its earnings results on Tuesday, August 8th. The biotechnology company reported ($0.15) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.29) by $0.14. The firm had revenue of $7.26 million for the quarter, compared to analysts’ expectations of $4.80 million. Analysts expect that Calithera Biosciences will post ($0.83) earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: This piece was originally published by Watch List News and is the sole property of of Watch List News. If you are accessing this piece on another publication, it was illegally stolen and republished in violation of U.S. & international copyright & trademark legislation. The correct version of this piece can be viewed at https://www.watchlistnews.com/calithera-biosciences-inc-nasdaqcala-lowered-to-strong-sell-at-bidaskclub/1477520.html.

In other Calithera Biosciences news, VP Keith Orford sold 2,120 shares of the business’s stock in a transaction on Monday, July 17th. The stock was sold at an average price of $18.31, for a total transaction of $38,817.20. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Over the last quarter, insiders have sold 3,470 shares of company stock worth $61,817. 16.30% of the stock is owned by company insiders.

Institutional investors have recently added to or reduced their stakes in the company. Legal & General Group Plc bought a new position in Calithera Biosciences during the second quarter worth $120,000. Raymond James Financial Services Advisors Inc. bought a new position in Calithera Biosciences during the first quarter worth $117,000. Nationwide Fund Advisors bought a new position in Calithera Biosciences during the first quarter worth $131,000. KCG Holdings Inc. bought a new position in Calithera Biosciences during the first quarter worth $144,000. Finally, Paloma Partners Management Co bought a new position in Calithera Biosciences during the first quarter worth $160,000. 54.51% of the stock is owned by institutional investors.

Calithera Biosciences Company Profile

Calithera Biosciences, Inc is a clinical-stage pharmaceutical company. The Company focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. It is engaged in developing agents that take advantage of the metabolic requirements of tumor cells and cancer-fighting immune cells, such as cytotoxic T-cells.

Analyst Recommendations for Calithera Biosciences (NASDAQ:CALA)

Receive News & Ratings for Calithera Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calithera Biosciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.